Compare BHE & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BHE | TMDX |
|---|---|---|
| Founded | 1979 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.6B |
| IPO Year | 1996 | 2019 |
| Metric | BHE | TMDX |
|---|---|---|
| Price | $82.36 | $83.89 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $55.00 | ★ $148.22 |
| AVG Volume (30 Days) | 384.7K | ★ 937.7K |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.94% | N/A |
| EPS Growth | N/A | ★ 382.18 |
| EPS | ★ 0.91 | 0.61 |
| Revenue | ★ $2,659,108,000.00 | $605,494,000.00 |
| Revenue This Year | $7.03 | $24.25 |
| Revenue Next Year | $6.57 | $18.75 |
| P/E Ratio | ★ $90.52 | $131.49 |
| Revenue Growth | 0.11 | ★ 37.13 |
| 52 Week Low | $35.97 | $60.11 |
| 52 Week High | $100.41 | $156.00 |
| Indicator | BHE | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 49.46 | 58.69 |
| Support Level | $79.59 | $66.18 |
| Resistance Level | $87.59 | $140.79 |
| Average True Range (ATR) | 4.22 | 4.14 |
| MACD | 0.59 | 0.63 |
| Stochastic Oscillator | 72.86 | 79.36 |
Benchmark Electronics Inc is engaged in product designing, engineering services, technology solutions, and manufacturing services (electronic manufacturing services (EMS) and precision technology services). It serves various industries, including aerospace & defense (A&D), medical technologies, complex industrials, semiconductor capital equipment, next-generation telecommunications, and high-end computing. Its geographical segments are the Americas, Asia, and Europe, of which key revenue is derived from the Americas.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.